These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36776898)

  • 21. Scaling eukaryotic cell-free protein synthesis achieved with the versatile and high-yielding tobacco BY-2 cell lysate.
    Gupta MD; Flaskamp Y; Roentgen R; Juergens H; Armero-Gimenez J; Albrecht F; Hemmerich J; Arfi ZA; Neuser J; Spiegel H; Schillberg S; Yeliseev A; Song L; Qiu J; Williams C; Finnern R
    Biotechnol Bioeng; 2023 Oct; 120(10):2890-2906. PubMed ID: 37376851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles.
    Tang S; Xuan B; Ye X; Huang Z; Qian Z
    Sci Rep; 2016 May; 6():25741. PubMed ID: 27170066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of HBc virus-like particles as modular nanocarrier by intein-mediated trans-splicing.
    Wang Z; Tang S; Yue N; Qian Z; Zhou S
    Biochem Biophys Res Commun; 2021 Jan; 534():891-895. PubMed ID: 33213839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line.
    Hirschberg S; Ghazaani F; Ben Amor G; Pydde M; Nagel A; Germani S; Monica L; Schlör A; Bauer H; Hornung J; Voetz M; Dwai Y; Scheer B; Ringel F; Kamal-Eddin O; Harms C; Füner J; Adrian L; Pruß A; Schulze-Forster K; Hanack K; Kamhieh-Milz J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    Hassebroek AM; Sooryanarain H; Heffron CL; Hawks SA; LeRoith T; Cecere TE; Stone WB; Walter D; Mahsoub HM; Wang B; Tian D; Ivester HM; Allen IC; Auguste AJ; Duggal NK; Zhang C; Meng XJ
    J Med Virol; 2023 Feb; 95(2):e28503. PubMed ID: 36655751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins.
    Peyret H; Gehin A; Thuenemann EC; Blond D; El Turabi A; Beales L; Clarke D; Gilbert RJ; Fry EE; Stuart DI; Holmes K; Stonehouse NJ; Whelan M; Rosenberg W; Lomonossoff GP; Rowlands DJ
    PLoS One; 2015; 10(4):e0120751. PubMed ID: 25830365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles.
    Dhanasooraj D; Kumar RA; Mundayoor S
    Int J Nanomedicine; 2013; 8():835-43. PubMed ID: 23486691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity.
    Li M; Liang Z; Chen C; Yu G; Yao Z; Guo Y; Zhang L; Bao H; Fu D; Yang X; Wang H; Xue C; Sun B
    ACS Nano; 2022 Jul; 16(7):10482-10495. PubMed ID: 35763693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.
    Strods A; Ose V; Bogans J; Cielens I; Kalnins G; Radovica I; Kazaks A; Pumpens P; Renhofa R
    Sci Rep; 2015 Jun; 5():11639. PubMed ID: 26113394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.
    Moradi Vahdat M; Hemmati F; Ghorbani A; Rutkowska D; Afsharifar A; Eskandari MH; Rezaei N; Niazi A
    Biotechnol Rep (Amst); 2021 Mar; 29():e00605. PubMed ID: 33732633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
    Luo H; Ma Y; Bi J; Li Z; Wang Y; Su Z; Gerstweiler L; Ren Y; Zhang S
    Vaccine; 2024 Sep; 42(22):125992. PubMed ID: 38811268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus-like Particle Vaccines and Platforms for Vaccine Development.
    Kheirvari M; Liu H; Tumban E
    Viruses; 2023 May; 15(5):. PubMed ID: 37243195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A DNA replicon system for rapid high-level production of virus-like particles in plants.
    Huang Z; Chen Q; Hjelm B; Arntzen C; Mason H
    Biotechnol Bioeng; 2009 Jul; 103(4):706-14. PubMed ID: 19309755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice.
    Sominskaya I; Skrastina D; Petrovskis I; Dishlers A; Berza I; Mihailova M; Jansons J; Akopjana I; Stahovska I; Dreilina D; Ose V; Pumpens P
    PLoS One; 2013; 8(9):e75938. PubMed ID: 24086668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-Specific Modification of Virus-Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity.
    Cheng K; Ma N; Liang J; Ma X; Feng Q; Liu G; Xu C; Tang M; Zhang L; Gao X; Xu J; Wang C; Zhu F; Wang X; Li X; Zhao X; Nie G
    Small; 2023 Jun; 19(23):e2300125. PubMed ID: 36879481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
    Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
    J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.